Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of citral in preparation of medicament for treating biliary tract diseases

A technology of citral and medicine, which is applied in the application field of citral in the preparation of medicines for treating biliary tract diseases, and can solve the problems of undeveloped medicines and no reports, etc.

Inactive Publication Date: 2013-03-13
张明发
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Citral has a simple chemical structure and is easy to synthesize. It has been widely used as a spice and a chemical raw material. Although it has certain pharmacological effects, it has not been developed into a drug, especially as a drug for the treatment of biliary system diseases, and has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of citral in preparation of medicament for treating biliary tract diseases
  • Application of citral in preparation of medicament for treating biliary tract diseases
  • Application of citral in preparation of medicament for treating biliary tract diseases

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental Example 1: Promoting bile secretion in rats and its effects on bile components

[0021] 1. The effect of one administration

[0022] Thirty-seven male rats, weighing 219±15g, were divided into 5 groups. After urethane anesthesia, bile duct intubation was performed, and after 0.5 hours of equilibration, the bile flow before the drug was collected for 0.5 hours, and collected after duodenal administration of citral, ursodeoxycholic acid or 0.5% Tween-80 Every 0.5h of flow, continuous 4h. Comparing the flow of every 0.5h with the flow before drug (flow after drug / flow before drug), the outflow rate can be obtained. Then compared with the corresponding phase of the control group by t test, the results are shown in Table 1.

[0023] Table 1 The effect of one-time duodenal administration of citral on bile secretion in anesthetized rats (M ± S)

[0024]

[0025] * p** p△ p△△ p<0.01 (compared with ursodeoxycholic acid group).

[0026] 2. The effect of repe...

experiment example 2

[0036] Experimental Example 2: Inhibition of Gallstone Formation in Mice

[0037]104 mice, half male and half male, weighing 18.8±1.6g, were divided into 5 groups. Except for the blank control group fed with normal diet, the mice in the other 4 groups were fed with stone-causing diet. Each animal was fed with 6 g of feed per day. The formulation of the stone-causing feed is: add 1% cholesterol and 0.5% cholic acid to the normal feed. The medication group was fed with citral or ursodeoxycholic acid, while the model-making control group was fed with solvent 0.5% Tween-80. During the 4th week of the experiment, blood was collected and the gallbladder was removed under anesthesia, the serum total cholesterol content and serum alanine aminotransferase level were measured, and gallstone formation in the gallbladder was observed. From the 4-week experimental results in Table 4, it can be seen that both ursodeoxycholic acid and citral have the effect of inhibiting the formation of ...

experiment example 3

[0041] Experimental Example 3: Dissolving human gallstones in a test tube

[0042] The tested drugs were all dissolved with Tween-80, and the content of Tween-80 in the prepared suspension was 0.5%. All medicinal solutions were adjusted to pH 8.5 with 0.4% NaOH. The human mixed gallstones obtained from surgery were washed and placed in an oven at 60°C with constant weight, and then arranged according to shape, color and weight, and then randomly divided into groups. Put a gallstone into a stoppered test tube, add 1ml of the test drug, shake it 3-4 times a day, change the drug solution once a day, take out the gallstone after 2 weeks, wash it, put it in an oven at 60°C, and dry it Weigh after the constant weight, and the difference between the gallstones weighed twice is the weight of the gallstones dissolved. Data were subjected to between-group t-tests (Table 5). The results showed that both the citral 0.5ml% group and the ursodeoxycholic acid 0.5g% group could dissolve hu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides the application of citral to the preparation of a medicament for treating biliary tract diseases.

Description

field of invention [0001] The invention belongs to the field of drugs for the hepatobiliary system, and in particular relates to the application of citral in the preparation of drugs for treating diseases of the biliary system. Background of the invention [0002] Biliary system disease is a frequently-occurring and common disease that seriously endangers people's health in my country, and its incidence rate ranks among the best in general surgery. As far as gallstone patients are concerned, they account for about 10.5% of the total number of inpatients in general surgery, and the incidence rate of the elderly over 80 years old can reach 23%, and the incidence rate is still on the rise. Japan's autopsy statistics in 1979-1980 found that 16-17% had cholelithiasis. The natural incidence of cholelithiasis in my country is about 10%, more than half of which are asymptomatic cholelithiasis, but the most worrying problem in asymptomatic cholelithiasis is the occurrence of acute c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/11A61P1/16
Inventor 张明发沈雅琴
Owner 张明发
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com